TALAPRO-2 trial

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

TALAPRO-2 trial

Apr 4, 2025, 10:16 | Science

Neeraj Agarwal: Patient-reported QOL results in phase 3 TALAPRO-2 trial

Shilpa Gupta, Director of Genitourinary Oncology and a Professor of Medicine at Cleveland Clinic, reshared a…

Feb 23, 2025, 01:54 | Blog

“Science in Seconds” with Bradley McGregor - ASCO

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: In our latest “Science…

Feb 8, 2025, 12:17 | Blog

Amol Akhade: What is interesting in ASCO GU25

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…

Dec 6, 2023, 13:54 | Insight

Yüksel Ürün: The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for metastatic castration-resistant prostate cancer with HRR gene alterations

Yüksel Ürüna, Professor at Ankara University School of Medicine, shared on X/Twitter: "The TALAPRO-2 trial shows…

All: 4 Posts: 1 - 100

'

Where to Study to Become ASCO President: 2025 Institutional Rankings

'

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

'

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

'

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book

'

April is Head and Neck Cancer Awareness Month

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023